Receive our newsletter – data, insights and analysis delivered to you
June 15, 2009

All Elesclomol Rights Returned to Synta

Biopharmaceutical company Synta and GlaxoSmithKline (GSK) have ended collaboration on the clinical development and commercialisation of elesclomol, effective no later than 10 September 2009. Worldwide rights to elesclomol will now be reverted to Synta, which may pay GSK a low single-digi

By cms admin

Biopharmaceutical company Synta and GlaxoSmithKline (GSK) have ended collaboration on the clinical development and commercialisation of elesclomol, effective no later than 10 September 2009.

Worldwide rights to elesclomol will now be reverted to Synta, which may pay GSK a low single-digit royalty on any potential future sales of elesclomol.

Synta president and CEO Safi Bahcall said that a meeting would be conducted to review the data from the SYMMETRY trial and additional results later this year, and these will be used to choose an informed path forward for the programme.

“While we are continuing to evaluate the potential of elesclomol, we are focusing our resources on the other programmes in our portfolio, particularly our Hsp90 programme, for which we expect to initiate a number of new clinical trials in the near term,” Bahcall said.

“We expect to report more on additional data and plans for the programme later in 2009.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU